Silexion’s SIL204 Raises MHC-I Expression at 60nM in KRAS G12R Pancreatic Cells
Preclinical data show Silexion’s SIL204 at 60nM induces a statistically significant increase in MHC-I surface expression in KRAS G12R-mutated human pancreatic cancer cells. These findings support potential combination strategies with anti-PD-1 agents to enhance immune recognition of refractory pancreatic tumors.
1. Preclinical Immuno-Oncology Study
On May 14, Silexion reported that treatment of KRAS G12R-mutated human pancreatic cancer cells with 60nM SIL204 led to a statistically significant upregulation of MHC-I (HLA-ABC) as measured by flow cytometry, indicating enhanced antigen presentation potential.
2. Next Steps and Clinical Path
The observed MHC-I increase suggests SIL204 could restore immune visibility of KRAS-driven tumors and support combination trials with PD-1 inhibitors such as pembrolizumab, with Silexion planning to advance SIL204 into clinical evaluation for locally advanced pancreatic cancer in upcoming trials.